Mirae Asset Global Investments Co., Ltd. Autolus Therapeutics PLC Transaction History
Mirae Asset Global Investments Co., Ltd.
- $28 Billion
- Q2 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 7,746 shares of AUTL stock, worth $13,168. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7,746
Previous 5,790
33.78%
Holding current value
$13,168
Previous $8,000
112.5%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding AUTL
# of Institutions
100Shares Held
164MCall Options Held
0Put Options Held
39.3K-
Wellington Management Group LLP Boston, MA27.1MShares$46.1 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$34.8 Million0.22% of portfolio
-
Mak Capital One LLC New York, NY17MShares$28.8 Million5.54% of portfolio
-
Deep Track Capital, LP Greenwich, CT16.9MShares$28.6 Million1.36% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$28.3 Million98.24% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $155M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...